Skip to Content
Merck
CN

UC208

6-Hydroxywarfarin

Synonym(s):

3-(α-Acetonylbenzyl)-4,6-dihydrocoumarin, 4-6-Dihydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C19H16O5
CAS Number:
17834-02-5
Molecular Weight:
324.33
UNSPSC Code:
12161501
PubChem Substance ID:
329827657
MDL number:
MFCD00272665

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C19H16O5/c1-11(20)9-14(12-5-3-2-4-6-12)17-18(22)15-10-13(21)7-8-16(15)24-19(17)23/h2-8,10,14,21-22H,9H2,1H3

SMILES string

CC(=O)CC(c1ccccc1)C2=C(O)c3cc(O)ccc3OC2=O

InChI key

IQWPEJBUOJQPDE-UHFFFAOYSA-N

color

white

mp

119-120 °C

solubility

DMSO: soluble

storage temp.

2-8°C

Biochem/physiol Actions

CYP1A2/2C9 metabolite of (R)-warfarin

Packaging

Bottomless glass bottle. Contents are inside inserted fused cone.

Preparation Note

6-Hydroxywarfarin is soluble in DMSO.

pictograms

CorrosionExclamation mark
GHS05,GHS07

signalword

Danger

hcodes

H302,H318

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BGBC2178V
1385501V
1385501
017K3258
085K1338

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Abdul Naveed Shaik et al.
Journal of pharmaceutical sciences, 105(6), 1976-1986 (2016-04-23)
The anticoagulant drug warfarin and the lipid-lowering statin drugs are commonly co-administered to patients with cardiovascular diseases. Clinically significant drug-drug interactions (DDIs) between these drugs have been recognized through case studies for many years, but the biochemical mechanisms causing these
A E Rettie et al.
Chemical research in toxicology, 5(1), 54-59 (1992-01-01)
Previous kinetic studies have identified a high-affinity (S)-warfarin 7-hydroxylase present in human liver microsomes which appears to be responsible for the termination of warfarin's biological activity. Inhibition of the formation of (S)-7-hydroxywarfarin, the inactive, major metabolite of racemic warfarin in
Steven Lane et al.
British journal of clinical pharmacology, 73(1), 66-76 (2011-06-23)
Warfarin is a drug with a narrow therapeutic index and large interindividual variability in daily dosing requirements. Patients commencing warfarin treatment are at risk of bleeding due to excessive anticoagulation caused by overdosing. The interindividual variability in dose requirements is
Development of a method for the analysis of warfarin and metabolites in plasma and urine.
J X de Vries et al.
American clinical laboratory, 14(7), 20-21 (1995-06-07)
J F Darbyshire et al.
Drug metabolism and disposition: the biological fate of chemicals, 24(9), 1038-1045 (1996-09-01)
The effect of branch pathways on the observed intramolecular isotope effect and deuterium retention associated with 6- and 7-hydroxylation of selectively monodeuterated (R)- and (S)-warfarin with cytochrome P450 (CYP) 2C9 and CYP1A2 were studied. cDNA-expressed CYP2C9 was incubated with enantiomerically
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service